Peter Attia: A physician and world expert in healthspan and longevity, author of the bestselling book Outlive and host of The Drive podcast. He spent his early career in immunology and surgical oncology research.
What this episode covers
The second installment of Huberman and Attia's Journal Club, where each host presents a paper. Huberman covers a Nature Mental Health study of 85,000+ UK Biobank participants showing that daytime light exposure and nighttime dark exposure have independent, additive effects on psychiatric outcomes including depression, self-harm, and psychosis. Attia presents the landmark 2010 New England Journal of Medicine ipilimumab (anti-CTLA-4) trial in metastatic melanoma, using it to explain how the immune system, cancer evasion, and checkpoint inhibitors work. They dig into how to read scientific figures, error bars, odds ratios, and reverse causality, and weave in tangents on light, supplements, artificial sweeteners, and immunotherapy's future.
The guest's own work
Outlive
Peter Attia
“Dr Peter Attia is a medical doctor who is a world expert in all things health span and lifespan he is the author of the bestselling book Outlive”— Andrew Huberman
Also referenced (named, not recommended)
TUO Light Bulb
TUO
“aside from one company out there which by the way I have no relationship to it's called the TUO and that light bulb was developed by the biologist”— Andrew Huberman
Carbon
Lane Norton
“Lane Norton's app carbon I have no financial relationship to it I use it and it's taught me wow like I consume a lot of calories”— Andrew Huberman
Pilot V5/V7 Pen
Pilot
“I'm such a nerd I always have one of these pilot V5 V7s in my pocket on my pocket of my hip and then my pockets are always filled”— Peter Attia
Yervoy (ipilimumab)
Bristol-Myers Squibb
“the drug we're going to talk about today is an anti-ctla4 drug there is another drug that came along shortly thereafter that is an anti-pd1 drug”— Peter Attia
Keytruda (pembrolizumab)
Merck
“a second drug came along that is an anti-pd1 drug that drug is called Keytruda that drug turned out to be even better and had even a greater response rate”— Peter Attia
Big reveals from this episode
- Huberman calls wearing blue blockers in the middle of the day 'the worst thing you could possibly do.'
- Huberman reveals a famous Harvard study claiming light behind the knee shifts circadian rhythm was later retracted, which most people don't know.
- Attia admits he has 'softened' his hardline no-blue-light stance, now arguing what you do on your phone matters more than its brightness.
- Both estimate light is roughly 65-80% causal (not just correlated) for the mental-health effects, despite reverse-causality concerns.
- Attia's stark takeaway: overall survival for metastatic solid-organ tumors is still 0% today, the same as in 1970, drugs only extend median survival.
- Attia shares a friend with Lynch syndrome whose Keytruda treatment so completely activated his immune system it destroyed his pancreas, leaving him with type 1 diabetes but cancer-free 10 years later.
- Attia reframes cancer immunotherapy as a 'longevity problem of T cells', needing cells old enough to recognize the enemy but young enough to kill.
Worth remembering
- Noon sun on a clear day can exceed 100,000 lux (up to 300,000), while bright indoor environments are only ~4,000-6,000 lux.
- An overcast outdoor day still averages ~100,000 lux because the circadian system sums photons over time rather than reacting instantly.
- People now spend about 90% of their daytime indoors, where it is too dim by day and too bright by night.
- A bright full-moon night is still under 100 lux; candlelight runs roughly 50-200 lux.
- In the study, the highest quartile of nighttime light raised major depressive symptoms ~25%, while the highest daytime-light quartile cut them ~20%.
- Almost every suicide victim's circadian rhythm appears nearly inverted in the days beforehand, even in non-bipolar individuals.
- Lung, breast, prostate, colorectal, and pancreatic cancers cause more than 50% of cancer deaths in Americans.
- At least 80% of solid-organ tumors produce antigens the immune system can recognize, yet still evade destruction.
- The ipilimumab trial extended median survival by only ~4 months (10 vs 6.4 months) but produced a 31% reduction in mortality risk.
- Melanoma and kidney cancer respond best to immunotherapy because they carry far more mutations, creating more recognizable antigens.